Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Abstract

Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

What is claimed is: 
     
         1 .- 8 . (canceled) 
     
     
         9 .- 13 . (canceled) 
     
     
         14 . A method for treating obesity and obesity-related disorders in animals comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of a compound of  claim 23 , or  24  or a pharmaceutically acceptable salt thereof. 
     
     
         15 . A method for treating or delaying the progression or onset of Type 2 diabetes and diabetes-related disorders in animals comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of a compound of  claim 23 , or  24  or a pharmaceutically acceptable salt thereof. 
     
     
         16 . A method for treating obesity and obesity-related disorders in animals comprising the step of administering to an animal in need of such treatment a pharmaceutical composition of claim  9 . 
     
     
         17 . A method for treating or delaying the progression or onset of Type 2 diabetes and diabetes-related disorders in animals comprising the step of administering to an animal in need of such treatment a pharmaceutical composition of claims  9 . 
     
     
         18 - 22 . (canceled) 
     
     
         23 . A pharmaceutically acceptable salt of a compound (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol. 
     
     
         24 . A pharmaceutically acceptable salt of a compound (1S,2S,3S,4S,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol.